The 26 most recent market catalysts affecting $RVMD, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 75
Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target
Goldman Sachs analyst Andrea Newkirk reinstated a 'Buy' rating on Revolution Medicines (RVMD) and announced a $267 price target. This is a significant positive development for RVMD…
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 65
B of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $265
B of A Securities, through analyst Alec Stranahan, has maintained its 'Buy' rating on Revolution Medicines (RVMD) and significantly raised its price target from $225 to $265. This …
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 95
Revolution Medicines Says FDA Granted Breakthrough Therapy Designation To RASONQUE In Combination With Gemcitabine And Nab-Paclitaxel For Treatment-Naive Metastatic Pancreatic Adenocarcinoma
The FDA's Breakthrough Therapy Designation is a significant regulatory milestone, indicating preliminary clinical evidence of substantial improvement over available therapies for a…
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 65
Morgan Stanley Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $255
Morgan Stanley's initiation of coverage on Revolution Medicines (RVMD) with an 'Overweight' rating and a substantial $255 price target is a significant event for the company. This …
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 55
Stifel Maintains Buy on Revolution Medicines, Raises Price Target to $230
Stifel's analyst Laura Prendergast maintained a 'Buy' rating for Revolution Medicines (RVMD) and raised the price target from $215 to $230. This action signals a positive outlook f…
Sep 2, 2026
Corporate Catalyst
Bearish
Impact 55
Why Are 42% of US Cancer Patients Draining Their Life Savings in Two Years? Bernie Sanders Has a $400,000 Answer
Senator Bernie Sanders has publicly criticized the high cost of new cancer drugs, specifically citing Revolution Medicines' (RVMD) newly approved pancreatic cancer drug, Rasonque, …
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $275
This 8-K filing discloses that Needham, through analyst Ami Fadia, has maintained a 'Buy' rating on Revolution Medicines (RVMD) and raised its price target from $240 to $275. This …
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on Revolution Medicines, Raises Price Target to $265
UBS analyst Michael Yee maintained a 'Buy' rating on Revolution Medicines (RVMD) and raised the price target from $220 to $265. This action indicates a strengthened positive outloo…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $275
Guggenheim analyst Michael Schmitz has raised the price target for Revolution Medicines (RVMD) from $240 to $275 while maintaining a 'Buy' rating. This action indicates a strengthe…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 95
Revolution Medicines Stock Trades Higher Following Landmark FDA Approval for Pancreatic Cancer Drug
Revolution Medicines (RVMD) has received FDA approval for Rasonque, its pancreatic cancer drug, marking a significant milestone as the first approved targeted therapy from a new cl…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 55
Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $260
Oppenheimer analyst Jay Olson has maintained an 'Outperform' rating on Revolution Medicines (RVMD) and raised the price target from $230 to $260. This action signals a strengthened…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 65
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $251
RBC Capital analyst Leonid Timashev has maintained an Outperform rating on Revolution Medicines (RVMD) and significantly raised the price target from $203 to $251. This action indi…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 55
Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $225
Wedbush analyst Robert Driscoll has updated his outlook on Revolution Medicines, increasing the price target for RVMD from $201 to $225 and reaffirming an Outperform rating. This a…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $239
Truist Securities analyst Gregory Renza maintained a 'Buy' rating on Revolution Medicines and raised the price target from $231 to $239. This action signals continued bullish senti…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 65
Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $320
Evercore ISI Group's analyst Cory Kasimov maintained an 'Outperform' rating on Revolution Medicines (RVMD) and raised the price target from $230 to $320. This significant increase …
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 95
Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug
Revolution Medicines (RVMD) announced FDA approval for Rasonque (daraxonrasib), a novel pancreatic cancer drug. This is a major milestone as Rasonque is the first approved targeted…
Aug 21, 2026
Corporate Catalyst
Bullish
Impact 55
Bernstein Maintains Market Perform on Revolution Medicines, Raises Price Target to $179
Bernstein analyst Jeffrey Walch increased the price target for Revolution Medicines (RVMD) from $151 to $179, signaling an improved valuation outlook for the company. Despite the h…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $231
Truist Securities analyst Gregory Renza maintained a 'Buy' rating on Revolution Medicines (RVMD) and raised the price target from $210 to $231. This action signals a continued posi…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $203
RBC Capital analyst Leonid Timashev maintained an 'Outperform' rating on Revolution Medicines (RVMD) and raised the price target from $182 to $203. This action signals a strengthen…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $201
Wedbush analyst Robert Driscoll has maintained an 'Outperform' rating for Revolution Medicines (RVMD) and raised the price target from $192.1 to $201. This action signals continued…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $230
Evercore ISI Group's analyst Cory Kasimov maintained an 'Outperform' rating for Revolution Medicines (RVMD) and raised the price target from $220 to $230. This action signals a pos…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $240
Needham analyst Ami Fadia has maintained a 'Buy' rating on Revolution Medicines (RVMD) and raised the price target from $236 to $240. This action signals continued bullish sentimen…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 95
Revolution Medicines Q2 EPS $(3.06) Misses $(1.98) Estimate
Revolution Medicines (RVMD) announced Q2 earnings per share of $(3.06), significantly missing the analyst consensus estimate of $(1.98). This 54.55% miss, coupled with a 133.59% in…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 75
Revolution Medicines shares are trading higher after Wedbush raised its price target on the stock from $181 to $192.1.
The Wedbush price target increase from $181 to $192.1 for Revolution Medicines (RVMD) is a strong positive catalyst, signaling increased analyst confidence in the company's valuati…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 55
Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $192.1
Wedbush analyst Robert Driscoll has raised the price target for Revolution Medicines (RVMD) from $181 to $192.1 while maintaining an Outperform rating. This action signals a positi…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $236
Needham analyst Ami Fadia has maintained a 'Buy' rating on Revolution Medicines (RVMD) and raised the price target from $235 to $236. This action signals continued analyst confiden…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.